The cardiometabolic disease market was valued at USD 35.94 Billion in 2025 driven by the rising prevalence of conditions like obesity, diabetes, and cardiovascular diseases as well as risk factors such as sedentary lifestyle and aging population across the 8 major markets. It is expected to grow at a CAGR of 5.40% during the forecast period 2026-2035 and attain a market value of USD 60.81 Billion by 2035.
Base Year
Historical Period
Forecast Period
The Centers for Disease Control and Prevention states that cardiometabolic diseases impact a significant number of adults in the United States, with about 11% diagnosed with diabetes and 10% diagnosed with cardiovascular disease. The rising prevalence of such conditions is anticipated to fuel the market growth in the forecast period.
Increased research initiatives and strategic collaborations can improve therapeutic options, which is likely to elevate the market value. For instance, in September 2023, The Broad Institute of MIT and Harvard partnered with Novo Nordisk to advance diabetes and cardiometabolic diseases research.
In March 2024, UMass Memorial Health announced a partnership with Google Cloud to utilize AI, ML, and data analytics for personalized care in cardiometabolic health. The integration of AI is poised to influence the market dynamics positively in the coming years.
Compound Annual Growth Rate
5.4%
Value in USD Billion
2026-2035
*this image is indicative*
Cardiometabolic disease includes obesity, diabetes, high blood pressure, and heart diseases, with shared risk factors such as unhealthy diet and genetics. Common types of cardiometabolic diseases include chronic heart failure, high blood pressure, type 2 diabetes, and obesity. Chronic heart failure occurs when the heart is unable to pump efficiently, whereas hypertension increases the likelihood of heart attacks. Comprehending and tackling these linked factors are crucial for successful prevention and control of cardiometabolic illnesses.
Treatment includes making lifestyle modifications, taking medications such as antihypertensives and metformin, and potentially undergoing surgical procedures including bariatric surgery. Ongoing surveillance and individualized approaches are essential for controlling risk factors and enhancing clinical outcomes. Medications can be given orally for high blood pressure and type 2 diabetes, or by injections for precise management of diabetes. In cases of emergencies such as heart failure, intravenous treatments may be administered. Modern technologies such as continuous glucose monitoring systems provide immediate management choices. The selection of how to administer medication relies on the patient's condition, adherence, and the treatment's efficacy.
Rising Prevalence of Cardiometabolic Disorders Drives Market Growth
The rising occurrence of cardiometabolic conditions is fueling expansion in the market for related diseases. The Centers for Disease Control and Prevention states that cardiometabolic diseases impact a significant number of adults in the United States, with about 11% diagnosed with diabetes and 10% diagnosed with cardiovascular disease (such as coronary heart disease, heart failure, or stroke). The increase in the prevalence of obesity, type 2 diabetes, and cardiovascular diseases is a result of lifestyle shifts towards poor diets and lack of physical activity. Further, older populations are more susceptible to these conditions, placing additional strain on healthcare systems. This has led to increased spending on healthcare and a need for efficient therapies, thereby stimulating innovation in the market.
Advancements in Treatment Options to Augment Cardiometabolic Disease Market Demand
Progress in treatment, such as the development of new medications for diabetes and heart health, is enhancing patient outcomes. In March 2024, the FDA approved Wegovy (semaglutide) injection for reducing the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and obesity/overweight. A calorie-restricted diet and increased physical activity should be followed while taking the medication for maximum effectiveness. Additionally, the rising preference for customized combination treatments and advancements in disease management through digital health solutions and telemedicine services are anticipated to propel the market growth in the forecast period. Changing clinical recommendations are guaranteeing that patients are getting the best possible treatment, showing a move towards individualized and comprehensive healthcare for improved handling of cardiometabolic conditions.
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
“Cardiometabolic Disease Market Report and Forecast 2026-2035” offers a detailed analysis of the market based on the following segments:
Market Breakup by Disease Type
Market Breakup by Treatment Type
Market Breakup by Route of Administration
Market Breakup by Distribution Channel
Market Breakup by Region
Market Segmentation Based on the Disease Type to Witness Growth
The cardiometabolic disease market can be divided based on disease type, such as chronic/congestive heart failure, hypertension, type 2 diabetes, obesity, and other conditions. Type 2 diabetes is widespread worldwide because of inactive lifestyles and unhealthy eating habits, resulting in growing emphasis on treatment and research for the disease. Pharmaceutical companies are increasingly focusing on creating new treatments for diabetes and related problems such as heart and kidney issues.
Distribution Channel Segment Represents Substantial Market Share
Based on the distribution chancel, the market is divided into hospital pharmacy, retail pharmacy, online pharmacy, and others. Retail pharmacies hold a significant market share as they are frequently utilized for prescription renewals and advice, whereas online pharmacies are becoming more popular for delivering medications to the patient’s home. Hospital pharmacies play a vital role in providing specialized medications and acute care services for a wide range of patients with cardiometabolic diseases.
Based on region, the market report covers United States, EU-4 (Germany, France, Italy, Spain), United Kingdom, Japan, and India.
The United States is expected to dominate the market share. Cardiometabolic diseases such as obesity, diabetes, and cardiovascular diseases are common in this region due to lifestyle behaviors but are aided by a well-developed healthcare system and research endeavors. Increased public health efforts and new treatment approaches are set to fuel the market growth in the region in the coming years.
The market in the Japan and India region is rapidly expanding because both the nations are concentrating on public health programs and advancements in treatment options to tackle these issues. In Japan, as the population ages, there is an increase in age-related cardiometabolic conditions, while in India, the growth of urban areas is causing a rise in obesity.
The key features of the market report include patent analysis, grant analysis, funding, and investment analysis, clinical trials analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Eli Lilly and Company, based in Indianapolis, is a pharmaceutical company that develops and sells healthcare products for various conditions. In July 2023, they announced an agreement to acquire Versanis Bio, a biopharmaceutical company focusing on cardiometabolic diseases.
Novartis AG is a Swiss multinational pharmaceutical company in Basel. The company got FDA approval in July 2023 to expand the use of its drug Leqvio® (inclisiran). The injectable medicine is now indicated for adults with high LDL-C at risk of heart disease, as an addition to diet and statins for hyperlipidemia treatment.
Novo Nordisk A/S, a Danish pharmaceutical company, focuses on discovering and developing biological medicines for diabetes, haemophilia, growth hormone disorders, rare blood and endocrine diseases, and obesity. In September 2023, Novo Nordisk partnered with The Broad Institute to research diabetes and cardiometabolic diseases in the United States. The alliance aims to identify drug targets for type 2 diabetes subtypes and genetic causes of cardiac fibrosis.
Merck & Co., Inc. is an American pharmaceutical company based in Rahway, New Jersey. Merck focuses on developing and marketing prescription medicines, biologic therapies, vaccines, and animal health products. Their products target various health conditions such as cardiovascular issues, cancer, immune disorders, infectious diseases, and diabetes. In June 2024, Merck announced that they are prioritizing opportunities in the cardiometabolic drugs market, including weight-loss treatments.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other players in the market are Biocrates Life Sciences AG, Alnylam Pharmaceuticals, Inc, Arrowhead Pharmaceuticals, Inc, Dicerna Pharmaceuticals, Inc, Cardax, Inc, Boehringer Ingelheim International GmbH, Kowa Company, Ltd, Allergan Inc, AstraZeneca Plc, Pfizer Inc, and Sanofi SA.
Von Hippel-Lindau Disease Market
Peripheral Artery Disease Market
Upto 15% Off
USD
$3299 $2969
$5499 $4949
$6999 $5949
$8199 $6969
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Disease Type |
|
| Breakup by Treatment Type |
|
| Breakup by Route of Administration |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share